- Home
- LYB vs DVA Comparison
LYB vs DVA Comparison
Compare LYB & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYB | DVA |
|---|---|---|
| Founded | 1955 | 1994 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2B | 14.9B |
| IPO Year | 2010 | 2003 |
Fundamental Metrics
Financial Performance| Metric | LYB | DVA |
|---|---|---|
| Price | $62.00 | $233.43 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 17 | 4 |
| Target Price | $69.35 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 4.7M | 701.3K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.38 | ★ 2.87 |
| Revenue | ★ $30,153,000,000.00 | $13,643,069,000.00 |
| Revenue This Year | $5.55 | $3.85 |
| Revenue Next Year | N/A | $3.07 |
| P/E Ratio | $164.00 | ★ $80.86 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $41.58 | $101.00 |
| 52 Week High | $83.94 | $239.64 |
Technical Indicators
Market Signals| Indicator | LYB | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 68.53 | 61.09 |
| Support Level | $42.06 | $145.58 |
| Resistance Level | $67.91 | $239.64 |
| Average True Range (ATR) | 1.65 | 5.75 |
| MACD | 1.36 | -1.30 |
| Stochastic Oscillator | 100.00 | 49.41 |
Price Performance
Historical ComparisonAbout LYB LyondellBasell Industries NV (Netherlands)
LyondellBasell is a petrochemical producer with operations in the United States, Europe, and Asia. The company is the world's largest producer of polypropylene and also a major producer of polyethylene and propylene oxide. Its chemicals are used in various consumer and industrial end products. Well over half of LyondellBasell's production comes from its North American operations.
About DVA DaVita Inc.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.